Current status of research on nonalcoholic fatty liver disease in China
-
摘要: 随着非酒精性脂肪性肝病(NAFLD)患病率的不断增加,公众的重视程度得到提高,相关研究逐渐增多,也取得了一些重要的进展。介绍了近5年来,我国在NAFLD的流行病学、危险因素、发病机制、无创性诊断、治疗及相关肝硬化和肝癌等方面重要的研究成果,了解我国的研究现状。指出与国际相比,我国相关临床和基础研究还存在一定的差距,尤其在公众的认知及医务工作者的重视度等方面;未来还应加强在流行病学、发病机制、患者的管理及药物治疗等方面的研究。Abstract: With the increasing prevalence rate of nonalcoholic fatty liver disease( NAFLD),this disease has been taken more seriously,more and more studies have been carried out in this field,and some important progress has been made. This article introduces the important research findings in the epidemiology,risk factors,pathogenesis,noninvasive diagnosis,and treatment of NAFLD,as well as related liver cirrhosis and hepatocellular carcinoma in China within the past five years,in order to know the current status of related research. This article points out that there still exists a certain gap between related clinical and basic research in China and the rest of the world,especially in the public's perception and the medical workers' emphasis on NAFLD. In the future,the research on epidemiology,pathogenesis,patient management,and drug therapies should be enhanced.
-
Key words:
- fatty liver /
- China /
- review
-
[1]YANG RX,FAN JG.Current epidemic status of nonalcoholic fatty liver disease[J].J Clin Intern Med,2015,32(5):293-296.(in Chinese)杨蕊旭,范建高.非酒精性脂肪性肝病的流行现状[J].临床内科杂志,2015,32(5):293-296. [2]LI F,CAI XB,FAN JG,et al.Prevalence of metabolic disorders in individuals with fatty liver at different age stages[J].Chin Hepatol,2012,17(7):470-473.(in Chinese)李锋,蔡晓波,范建高,等.不同年龄层次脂肪肝患者中代谢异常发生情况分析[J].肝脏,2012,17(7):470-473. [3]HOU SQ,XIN YN,XUAN SY,et al.Current status of incidence of fatty liver disease and its influencing factors in populations living in coastal regions:a preliminary study based on physical examination records[J].Chin J Hosp Stat,2013,20(3):199-201.(in Chinese)侯素青,辛永宁,宣世英,等.基于体检档案对沿海地区人群脂肪性肝病发病现状及影响因素初探[J].中国医院统计,2013,20(3):199-201. [4]LI JP,DING YY,WANG BY,et al.Epidemiological survey of prevalence of fatty liver disease and its risk factors in urban population of northeast China[J].2011,20(7):617-620,623.(in Chinese)李金萍,丁媛媛,王炳元,等.东北地区城市脂肪肝的患病率及其危险因素的流行病学调查[J].胃肠病学和肝病学杂志,2011,20(7):617-620,623. [5]HE S,BAO W,SHAO M,et al.Risk factors for non-alcoholic fatty liver disease in a Chinese population[J].Acta Gastroenterol Belg,2011,74(4):503-508. [6]XIANG GQ,MENG XD,WANG BY,et al.Prevalence of fatty liver among people with different occupation in Shenyang[J].J Clin Hepatol,2010,26(3):283-285.(in Chinese)向国卿,孟晓丹,王炳元,等.沈阳市不同职业人群脂肪肝的流行现状分析[J].临床肝胆病杂志,2010,26(3):283-285. [7]ZHANG ZG,XUE L,ZHANG YX,et al.Analysis of the prevalence of nonalcoholic fatty liver disease in uygur civil servants in Urumqi[J].Modern Prevent Med,2012,39(8):1955-1957.(in Chinese)张泽高,薛黎,张跃新,等.乌鲁木齐市公务员非酒精性脂肪肝调查[J].现代预防医学,2012,39(8):1955-1957. [8]FAN JG,ZHOU Q,WO QH,et al.Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease[J].Chin J Hepatol,2010,18(9):676-679.(in Chinese)范建高,周琪,沃千红,等.人体质量指数及其变化与非酒精性脂肪性肝病发病的关系[J].中华肝脏病杂志,2010,18(9):676-679. [9]XU C,YU C,MA H,et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study[J].Am J Gastroenterol,2013,108(8):1299-1304. [10]ZHOU X,HOU DQ,DUAN JL,et al.Prevalence of nonalcoholic fatty liver disease and metabolic abnormalities in 387 obese children and adolescents in Beijing,China[J].Chin J Epidemiol,2013,34(5):446-450.(in Chinese)周歆,侯冬青,段佳丽,等.北京市387名肥胖中学生非酒精性脂肪肝等代谢异常罹患状况调查[J].中华流行病学杂志,2013,34(5):446-450. [11]SU L,LIU YL.Risk factors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus[J].Chin J Gen Prac,2010,9(1):47-49.(in Chinese)苏琳,刘玉兰.2型糖尿病患者合并非酒精性脂肪性肝病危险因素分析[J].中华全科医师杂志,2010,9(1):47-49. [12]HU CB,SHI JP.The relationship between fatty liver and hyperuricemia[J].Chin Hepatol,2011,16(3):202-205.(in Chinese)胡晨波,施军平.脂肪肝与高尿酸血症关系的探讨[J].肝脏,2011,16(3):202-205. [13]XU C,YU C,XU L,et al.High serum uric acid increases the risk for nonalcoholic fatty liver disease:a prospective observational study[J].PLo S One,2010,5(7):e11578. [14]XU C,WAN X,XU L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol,2015,62(6):1412-1419. [15]IHARA Y,YOSHIMURA M,MIYOSHI E,et al.Ectopic expression of N-acetylglucosaminyltransferaseⅢin transgenic hepatocytes disrupts apolipoprotein B secretion and induces aberrant cellular morphology with lipid storage[J].Proc Natl Acad Sci U S A,1998,95(5):2526-2530. [16]FU J,GERHARDT H,MCDANIEL JM,et al.Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice[J].J Clin Invest,2008,118(11):3725-3737. [17]ZHAN Y,ZHAO F,XIE P,et al.Mechanism of the effect of glycosyltransferase GLT8D2 on fatty liver[J].Lipids Health Dis,2015,14:43. [18]XU J,XIN YN,LYU WH,et al.Polymorphism rs738409 in PNPLA3 is associated with inherited susceptibility to non-alcoholic fatty liver disease[J].Chin J Hepatol,2013,21(8):619-623.(in Chinese)徐静,辛永宁,吕维红,等.PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性的关系[J].中华肝脏病杂志,2013,21(8):619-623. [19]ZHANG Y,CAI W,SONG J,et al.Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China[J].PLo S One,2014,9(10):e108381. [20]ZHANG H,CHEN L,XIN Y,et al.Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease:a meta-analysis[J].Hepat Mon,2014,14(10):e23100. [21]SHEN F,ZHENG RD,MI YQ.A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver[J].Chin J Hepatol,2014,22(12):926-931.(in Chinese)沈峰,郑瑞丹,宓余强,等.受控衰减参数诊断脂肪肝的临界值初探:一项多中心临床研究[J].中华肝脏病杂志,2014,22(12):926-931. [22]SHEN F,XU ZJ,PAN Q,et al.Influencing factors and reproducibility of controlled attenuation parameters in the evaluation of fatty liver disease using Fibro Scan[J].J Pract Hepatol,2013,16(1):59-62.(in Chinese)沈峰,徐正婕,潘勤,等.Fibro Scan R实施受控衰减参数评价脂肪肝的影响因素及重复性分析[J].实用肝脏病杂志,2013,16(1):59-62. [23]ZHU MF,LIU J,WANG J,et al.Effection of HBV on controlled attenuation parameters using Fibro Scan(R)[J].Chin J Exp Clin Virol,2014,28(1):7-9.(in Chinese)朱梦飞,刘静,王洁,等.HBV感染对Fibro Scan(R)实施受控衰减参数评价脂肪肝影响的研究[J].中华实验和临床病毒学杂志,2014,28(1):7-9. [24]LI H,WANG L,YAN X,et al.A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease[J].J Proteome Res,2011,10(6):2797-2806. [25]CAO W,ZHAO C,SHEN C,et al.Cytokeratin 18,alanine aminotransferase,platelets and triglycerides predict the presence of nonalcoholic steatohepatitis[J].PLo S One,2013,8(12):e82092. [26]Group of Fatty Liver and Alcoholic Liver Diseases,Society of Hepatology,Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志,2010,26(2):120-124. [27]CHALASANI N,YOUNOSSI Z,LAVINE JE,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Disease,American College of Gastroenterology,and the American Gastroenterological Association[J].Hepatology,2012,55(6):2005-2023. [28]FAN JG,FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol,2009,50(11):204-210. [29]LI L,DING HG.Clinical features of cirrhosis due to nonalcoholic steatohepatitis[J].J Clin Hepatol,2011,27(10):1032-1035.(in Chinese)李磊,丁惠国.20例非酒精性脂肪性肝硬化的临床特征分析[J].临床肝胆病杂志,2011,27(10):1032-1035. [30]ASCHA MS,HANOUNEH IA,LOPEZ R,et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].Hepatology,2010,51(6):1972-1978. [31]LIU J,JIN X,YU CH,et al.Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis[J].J Gastroenterol Hepatol,2010,25(3):613-618. [32]CHEN WT,ZHU G,PFAFFENBAEH K,et al.GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN[J].Oncogene,2014,33(42):4997-5005. [33]ZHENG L,YANG W,WU F,et al.Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma[J].Clin Cancer Res,2013,19(19):5372-5380. [34]QU KZ,ZHANG K,LI H,et al.Circulating microRNAs as biomarkers for hepatocellular carcinoma[J].J Clin Gastroenterol,2011,45(4):355-360. [35]FAN JG,ZHUANG H,HUANG Y,et al.Key words in the first“popular science edition”of guidelines for the prevention and treatment of fatty liver disease[J].Liver Doct,2015,(3):14-18.(in Chinese)范建高,庄辉,黄薏,等.全球首部“科普版”《脂肪肝防治指南》[J].肝博士,2015,(3):14-18. [36]ZENG MD,WANG BY,CHEN CW,et al.General characteristics and clinical practices of Chinese patients with non-alcoholic fatty liver disease[J].Chin J Hepatol,2011,19(5):362-366.(in Chinese)曾民德,王炳元,陈成伟,等.非酒精性脂肪性肝病患者基本特征及诊疗规范的调查研究[J].中华肝脏病杂志,2011,19(5):362-366. [37]Group of Fatty Liver and Alcoholic Liver Diseases,Society of Hepatology,Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].Chin Hepatol,2006,11(1):68-70.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].肝脏,2006,11(1):68-70.
本文二维码
计量
- 文章访问数: 2732
- HTML全文浏览量: 65
- PDF下载量: 544
- 被引次数: 0